Forbes is profiling the development work underway at the "unknown" PTC Therapeutics, one of this year's Fierce 15 [1]. The feature focuses on the progress of PTC124 in mid-stage trials for Duchenne muscular dystrophy, noting that it has the potential to address a myriad [2] of other genetic flaws as well.
- read the article [3] on PTC Therapeutics from Forbes
Related Articlex:
Genetic therapy could cure 1,800 diseases. Report [2]
Schering-Plough, PTC to collaborate. Report [4]
PTC inks deal with CV. Report [5]
Links:
[1] http://www.fiercebiotech.com/fierce15/2007/ptc-therapeutics
[2] http://www.fiercebioresearcher.com/story/genetic-therapy-could-cure-1800-diseases/2007-04-24?utm_source=related&utm_medium=internal
[3] http://members.forbes.com/forbes/2007/0917/072.html
[4] http://www.fiercebiotech.com/story/schering-plough-ptc-to-collaborate/2006-03-20
[5] http://www.fiercebiotech.com/story/spotlight-ptc-inks-deal-with-cv/2006-06-13